“FDA has banned LL-37.”

01 · Answer

Misleading

The person or group who asked FDA to consider LL-37 for its pharmacy-compounding list withdrew the request. That request was called a 503A nomination. Its withdrawal is not a ban. The current federal rule does not list LL-37. FDA plans an advisory-committee discussion before the end of February 2027. That discussion is not a final decision or drug approval.

What kind of evidence this is

Regulatory or product record. This answer uses an official regulator record or a specific product label.

What this answer covers

The U.S. pharmacy-compounding status as reviewed August 30, 2026; an advisory discussion is not a final FDA action. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.

Question type

Approval and status. Whether a specific product has an approval or another official status.